Solventum Co. (NYSE:SOLV) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. reduced its position in Solventum Co. (NYSE:SOLV) by 23.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 5,842 shares of the company’s stock after selling 1,815 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Solventum were worth $386,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of SOLV. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $125,488,000. Trian Fund Management L.P. boosted its holdings in shares of Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares during the period. Boston Partners acquired a new stake in shares of Solventum in the fourth quarter valued at approximately $110,378,000. Point72 Asset Management L.P. acquired a new stake in shares of Solventum in the third quarter valued at approximately $50,948,000. Finally, Nordea Investment Management AB raised its stake in shares of Solventum by 189.5% during the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after purchasing an additional 431,986 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wells Fargo & Company upped their price target on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Bank of America upped their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Piper Sandler upped their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Finally, The Goldman Sachs Group upped their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Trading Down 1.3 %

Shares of SOLV stock opened at $74.00 on Friday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The stock has a market cap of $12.80 billion and a P/E ratio of 26.91. The business has a fifty day simple moving average of $75.17 and a 200-day simple moving average of $71.56. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.